source
- Boehringer dual-acting obesity shot hits mark in Phase 3 trialSurvodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.BioPharma Dive · 3mo ago↗ source
- Rocket's PRV goes for $180M; Oruka targets $500M offeringRocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ...Endpoints · 3mo ago↗ source
- BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGFThe pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license and…